Continuous Glucose Monitoring in Inpatients

Hyperglycemia Clinical Trial

Official title:

Continuous Glucose Monitoring in Medical and Open-Heart Surgical Patients

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT06329297
• Other study ID #: NUR23-1005 INPTCGM1
• Status: Not yet recruiting
• Start date: April 2024
• Est. completion date: April 2025

Study information

• Verified date: March 2024
• Source: Parkview Health
• Contact: Philip Roberts
• Phone: 260-266-2261
• Email: Philip.roberts[@]parkview.com
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The purpose of this study is to contribute to current research regarding the feasibility and accuracy of CGM in the hospital setting for both the medical and cardiovascular intensive care (ICU) patient populations.

Description:

The use of continuous glucose monitors (CGM) in the outpatient setting has dramatically increased as these devices continue to improve in both ease of use, accessibility, and accuracy. Federal Drug Administration (FDA) clearance of certain devices has now been granted in both pregnancy and automated insulin delivery systems. As the world has embraced the safety and efficacy of continuous glucose monitors in the outpatient setting, health systems have turned attention to the potential of utilizing these devices to improve glycemic control in the hospital setting. With the announcement of the FDA granting enforcement discretion regarding the use of CGM technology in the hospital setting during the COVID-19 pandemic, the result was an abundance of research evaluating the potential of CGM longevity in the hospital setting. The Standards of Care in Diabetes: 2023 reported that "preliminary data suggests that CGM can significantly improve glycemic management and other hospital outcomes." Additionally, a systematic review of 32 studies evaluated the accuracy of CGM in the intensive care unit, with a consensus of moderate to good accuracy. CGM in the hospital setting could provide a valuable tool in reducing hypoglycemia, hyperglycemia, and increasing time spent in normoglycemia. Other potential benefits of CGM include a broader view of glucose patterns, capture of asymptomatic hypoglycemia, reduced length of stay, and decreased cost. The Diabetes Technology Society organized the Hospital Consensus Guideline Panel in 2020, with the final report including the recommendation for additional research on the accuracy, data management, and patient-centered outcomes of CGM use in the inpatient setting.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 80
• Est. completion date: April 2025
• Est. primary completion date: August 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Admitted patients 18 years of age or older
• Glucose management per Glucommander and/or receiving POC blood glucose testing
• Patients admitted to Medical 6 or elective or urgent open-heart surgery patients admitted to the Cardiovascular Intensive Care Unit (CVICU)

Exclusion Criteria:

• Patients less than 18 years of age
• Pregnant or currently breastfeeding
• Prisoners
• Patients unable to consent in English.
• Patients with a preexisting insulin pump on admission
• Active skin infection at the insertion site(s)

Related Conditions & MeSH terms

• Hyperglycemia

Intervention

Device:
• CGM monitor
blood glucose sensor used to monitor interstitial glucose

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Parkview Health

References & Publications (2)

Galindo RJ, Umpierrez GE, Rushakoff RJ, Basu A, Lohnes S, Nichols JH, Spanakis EK, Espinoza J, Palermo NE, Awadjie DG, Bak L, Buckingham B, Cook CB, Freckmann G, Heinemann L, Hovorka R, Mathioudakis N, Newman T, O'Neal DN, Rickert M, Sacks DB, Seley JJ, Wallia A, Shang T, Zhang JY, Han J, Klonoff DC. Continuous Glucose Monitors and Automated Insulin Dosing Systems in the Hospital Consensus Guideline. J Diabetes Sci Technol. 2020 Nov;14(6):1035-1064. doi: 10.1177/1932296820954163. Epub 2020 Sep 28. — View Citation

van Steen SC, Rijkenberg S, Limpens J, van der Voort PH, Hermanides J, DeVries JH. The Clinical Benefits and Accuracy of Continuous Glucose Monitoring Systems in Critically Ill Patients-A Systematic Scoping Review. Sensors (Basel). 2017 Jan 14;17(1):146. doi: 10.3390/s17010146. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	CGM vs point of care test (POCT) glucose	Continuous interstitial glucose monitor readings compared to point of care capillary blood glucose readings	from date of admission up to 7 days
Secondary	Slow downward trend arrow on CGM device	impact on hypoglycemia events	from date of admission up to 7 days

External Links

•   Diabetes Care in the Hospital: Standards of Care in Diabetes-2023